conducted a study on the ER+/HER2-low human breast cancer mouse xenotransplantation model, and the results showed that adding ET to the combination of anti-HER3 and anti-HER2 drugs could further improve the efficacy of tumor regression (55). Here, ERBB2 is linked to neoplasm.